Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.50 |
| ▸ | BCHE | P06276 | 10/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8011060 | 0.82 | ACHE (0.52) | ACHEBCHEPRMT6PLAUCYP2A6 | |
| SCHEMBL7998984 | 0.80 | ACHE (0.50) | ACHEBCHEPRMT6PLAUCYP2A6 | |
| SCHEMBL6214211 | 0.80 | ALDH1A1 (0.57) | ACHEBCHEPRMT6 | |
| SCHEMBL2458150 | 0.78 | ACHE (0.74) | ACHEBCHEPRMT6CYP2A6CYP2C19 | |
| SCHEMBL14433352 | 0.77 | — | — | |
| SCHEMBL5310160 | 0.76 | ACHE (0.46) | ACHEBCHEPRMT6PLAUCYP2A6 | |
| SCHEMBL8409438 | 0.74 | ACHE (0.49) | ACHEBCHEPRMT6PLAUCYP2A6 | |
| SCHEMBL7998986 | 0.73 | ACHE (0.57) | ACHEBCHEPRMT6CYP2A6CYP2C19 | |
| SCHEMBL10047419 | 0.72 | — | — | |
| SCHEMBL8011063 | 0.72 | ACHE (0.61) | ACHEBCHEPRMT6CYP2A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-02-02 | — | — | US | disclosed |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | PSEN2, CLN6, MAPT | ACHE 263/4885BCHE 344/4885PRMT6 2717/4885 |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | PSEN2, SNCA, MAPT | ACHE 307/4885BCHE 336/4885PRMT6 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.